A generic equivalent to Bristol-Myers Squibb’s entecavir (Baraclude) hepatitis B treatment has been approved by the FDA. Aurobindo Pharma’s generic entecavir will soon be available in 0.5 mg and 1 mg oral tablet strengths. Entecavir is a nucleoside analogue indicated … Continue reading →
A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate (TDF) can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus (HBV) infection, both in those with and without cirrhosis. Hepatocellular carcinoma (HCC) … Continue reading →
TUESDAY, Dec. 16, 2014 (HealthDay News) — Entecavir is more efficacious than lamivudine for preventing hepatitis B virus (HBV) reactivation among patients who are seropositive for the hepatitis B surface antigen with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, … Continue reading →
— Christine M. Kukka, Project Manager, HBV Advocate A four-year study of 355 patients treated with either tenofovir (Viread) or entecavir (Baraclude) found both antivirals to be highly effective in reducing viral loads, according to a report published in the … Continue reading →
